Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vera Therapeutics Inc Cl A (NQ: VERA )

48.48 +1.45 (+3.07%)
Streaming Delayed Price Updated: 2:39 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics Inc Cl A

< Previous 1 2 3 4 5 6 7 Next >
Why Is Immunology Disease Focused Vera Therapeutics Stock Trading Higher Today?
Vera Therapeutics' 72-week data from Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR. 
Via Benzinga
Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Thursday. Shares of Alaska Air Group, Inc. (NYSE: ALK) rose during Thursday’s session following upbeat earnings. 
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Recap: Vera Therapeutics Q3 Earnings
Via Benzinga
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
Why Vera Therapeutics Stock Soared by 22% This Week
Executive changes and a bullish analyst take combined to boost sentiment on the company. 
Via The Motley Fool
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... 
Via Benzinga
Exposures Product Safety
Vera Therapeutics' Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst
Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion... 
Via Benzinga
This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street
Is the stock's risk worth the potential reward? 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Synaptics To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics Scheduled to Present at November Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
From Vera Therapeutics
Via GlobeNewswire
Why Shares of Vera Therapeutics Jumped Tuesday
The stock bounced back Tuesday from a three-month low it hit on Monday. 
Via The Motley Fool
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi... 
Via Benzinga
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Vera Therapeutics Scheduled to Present at September Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2023
Via Benzinga
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
From Vera Therapeutics
Via GlobeNewswire
Around $8.5M Bet On Eagle Bulk Shipping? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed mostly higher on Thursday, there were a few notable insider trades. 
Via Benzinga
Why Shares of Vera Therapeutics Jumped Tuesday
The company announced early phase 2 trials information regarding its lead therapy. 
Via The Motley Fool
Vera Therapeutics Stock Is Trading Higher Today - Here's Why
On Saturday, Vera Therapeutics Inc (NASDAQ: VERA) announced that the Phase 2b ORIGIN trial of atacicept for the treatment of IgA nephropathy (IgAN) met its primary and key secondary endpoints, with... 
Via Benzinga
DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 250 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
2 Surging Healthcare Stocks With More Fuel in the Tank
These stocks climbed 74% and 78% over the past month and there could be more gains ahead. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.